GRAIL, Inc. (GRAL)
140.00
+2.63
(+1.91%)
USD |
NASDAQ |
Oct 13, 14:59
GRAIL Shareholders Equity (Quarterly) : 2.543B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.543B |
| March 31, 2026 | 2.501B |
| December 31, 2025 | 2.578B |
| September 30, 2025 | 2.240B |
| June 30, 2025 | 2.315B |
| March 31, 2025 | 2.414B |
| December 31, 2024 | 2.503B |
| September 30, 2024 | 2.588B |
| June 30, 2024 | 2.695B |
| March 31, 2024 | 3.739B |
| December 31, 2023 | 3.646B |
| September 30, 2023 |
| Date | Value |
|---|---|
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | 609.94M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Moderna, Inc. | 6.761B |
| Twist Bioscience Corp. | 445.74M |
| Prime Medicine, Inc. | 39.81M |
| Kailera Therapeutics, Inc. | 1.118B |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.844B |
| Total Liabilities (Quarterly) | 301.03M |
| Debt to Equity Ratio | 0.0359 |
| Current Ratio | 10.95 |
| Net Debt Paydown Yield | -0.18% |